BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Talks.cam//talks.cam.ac.uk//
X-WR-CALNAME:Talks.cam
BEGIN:VEVENT
SUMMARY:HE@Cam seminar: Christian Hill - Patient Access Scheme\, Managed A
 ccess Agreement and their influence on the approval trends of new medicine
 s\, devices and diagnostics - Christian Hill - CEO\, MAP Biopharma
DTSTART:20180611T140000Z
DTEND:20180611T150000Z
UID:TALK106054@talks.cam.ac.uk
CONTACT:David Wastlund
DESCRIPTION:Health Economics @ Cambridge presents Christian Hill\, CEO at 
 MAP Biopharma\, for a seminar on Patient Access Scheme\, Managed Access Ag
 reements and their influence on the approval trends of new medicines\, dev
 ices and diagnostics.\n\nInformation can also be found "here":http://www.p
 ublichealth.cam.ac.uk/june-11-christian-hill/\n\n*About the seminar:*\nThe
  role of market access is pivotal to ensure rapid and maintained access to
  medicines\, devices and diagnostics to all appropriate patients who would
  benefit from treatment at the right price. Approval trends have shown to 
 be greatly influenced by the introduction of Patient Access Schemes (PAS) 
 and Managed Access Arrangements (MAA).\n\nChanges to the regulatory landsc
 ape has allowed bodies such as NICE to issue guidance on technologies with
  an evidence base that is smaller or earlier in its evolution than has pre
 viously been the case. This has allowed patient access to certain interven
 tions earlier\, such as through the EMA’s ‘Adaptive Pathways’ scheme
 . However\, these methods will often have greater uncertainly regarding th
 e clinical and cost-effectiveness at the point of decision making.\n\nPAS 
 are agreements reached by life sciences companies\, reducing cost to the N
 HS\, enabling patients to access cost-effective and innovative interventio
 ns. MAAs are increasingly introduced when conclusions on reimbursement can
 not be made due to uncertainties in the clinical evidence and/or financial
  impact of an intervention and are designed to reduce the cost\, in partic
 ular with orphans\, ultra-orphans and cancer drugs. The same principles ar
 e beginning to be used with devices and diagnostics.\n\n*Christian Hill:*\
 nChristian is a seasoned Market Access professional with over 18 years of 
 experience in the International Biotech and Pharmaceutical industry. He ha
 s been involved in over 50 HTAs across Europe and has built up a strong ne
 twork of key influencers including EU and national agencies. Prior to co-f
 ounding MAP in 2012\, he led market access teams and submissions at InterM
 une\, Gilead\, Pfizer and Genzyme on a very broad range of products and di
 sease areas from chronic disease to ultra-orphan indications.\n\nChristian
  is a member of the Steering Group of EMIG (Ethical Medicines Industry Gro
 up) in the UK and Ireland\; he is also a member of the Board of EUCOPE (Eu
 ropean Confederation of Pharmaceutical Entrepreneurs).
LOCATION:Clinical School - Seminar room 10
END:VEVENT
END:VCALENDAR